ALGS
Q4 2026 EPS Estimate
$-2.44
Nov 5, 2026
Revenue Estimate
$5M
FY2029E EPS$0.57
FY2030E EPS$2.38

Analyst Sentiment

Wall St. Consensus
Buy
5 analysts·Limited coverage
65
Score
3 Buy (60%)2 Hold (40%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
360%
Hold
240%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$20.00
+189.4%
Consensus
$20.00
+189.4%
Bull
$20.00
+189.4%
12-Month Target Range5 analysts
$20.00$20.00$20.00
Current $6.91Consensus
Current Price
$6.91
Upside to Consensus
$13.09

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev-88.69%
EPS
FY2028
Rev+1180.07%
EPS
FY2029
Rev+241.90%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$36M$4M$52M$178M$237M
Low$34M$4M$47M$160M$213M
High$38M$5M$70M$240M$320M
EBITDA Avg$-62M$-51M$-4M$12M$39M
Low$-66M$-65M$-56M$11M$35M
High$-57M$-37M$61M$16M$52M
EBIT Avg$-63M$-52M$-6M$7M$30M
Low$-68M$-66M$-58M$6M$26M
High$-59M$-38M$59M$10M$43M
Net Income Avg$-63M$-52M$-6M$6M$24M
Low$-68M$-66M$-58M$5M$20M
High$-59M$-38M$47M$8M$34M
EPS Avg$-6.30$-5.18$-2.45$0.57$2.38
Low$-6.85$-6.71$-5.86$0.50$2.06
High$-5.93$-3.86$4.71$0.83$3.47
Analysts (Rev / EPS)5 / 54 / 54 / 52 / 12 / 1
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027
Revenue Avg$5M$537,500$220,000$220,000$910,000$4M
Low$5M$537,500$220,000$220,000$910,000$4M
High$5M$537,500$220,000$220,000$910,000$4M
EBITDA Avg$-23M$-19M$-17M$-17M$-13M$-11M
Low$-26M$-20M$-17M$-17M$-13M$-11M
High$-19M$-18M$-17M$-17M$-13M$-11M
EBIT Avg$-23M$-19M$-17M$-17M$-13M$-11M
Low$-26M$-21M$-17M$-17M$-13M$-11M
High$-19M$-18M$-17M$-17M$-13M$-11M
Net Income Avg$-23M$-19M$-17M$-17M$-13M$-11M
Low$-26M$-21M$-17M$-17M$-13M$-11M
High$-19M$-18M$-17M$-17M$-13M$-11M
EPS Avg$-2.19$-1.87$-1.63$-1.66$-1.26$-1.06
Low$-2.52$-1.97$-1.63$-1.66$-1.26$-1.06
High$-1.85$-1.76$-1.63$-1.66$-1.26$-1.06
Analysts (Rev / EPS)3 / 36 / 33 / 13 / 13 / 13 / 1

Earnings Surprises

Recent Analyst Actions

May 21, 2026Cantor Fitzgerald
Aligos Therapeutics initiated with an Overweight at Cantor Fitzgerald
Target:$20.00
+257.1%from $5.60
Jan 7, 2026UBS
UBS Starts Aligos Therapeutics Inc. (ALGS) at Buy
Target:$20.00
+128.3%from $8.76
Jan 6, 2023Piper Sandler
Piper Sandler Upgrades Aligos Therapeutics to Overweight, Raises Price Target to $3
Target:$3.00
+146.9%from $1.22
Jan 6, 2023Jefferies
Jefferies Upgrades Aligos Therapeutics to Buy, Raises Price Target to $3
Target:$3.00
+203.0%from $0.99
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.